New Research Reports

Quarterly Update Q2FY26

Quarterly Update Q1FY26

Laxmi Dental (Laxmiden) is distinguished as India’s only fully integrated provider of dental solutions, led by a highly experienced management team with extensive expertise in the field.

Quarterly Update Q3FY25

Initiating Coverage Report

IPO NOTE

Poly Medicure’s (PolyMed) Q1FY25 performance was boosted by exports (~23% YoY) while domestic business growth (~12% YoY) took a pause on high base. The company has commissioned four new plants that may double its device manufacturing capacity to 1.8bn units p.a by FY25 end.

Poly Medicure reported its all-time high revenues and EBITDA in Q1FY24 driven by solid performance across India (30% YoY growth) and Europe (35%). Softening of raw material prices fuelled a 220bps jump in gross margin. Ahead EBITDA margin is likely to be between 25-27%. Company will commercialise 4 manufacturing facilities in FY24 and launch 10-12 products in critical care segment, which will also likely drive growth and aid margin expansion.

Poly Medicure’s (Polymed) Q3FY23 performance beats our estimates on all fronts. Revenue grew 23.7% YoY to Rs2.8bn (I-Sec: Rs2.7bn) led by strong demand across segments. EBITDA margin improved 270bps YoY and 140bps QoQ to 24.9%, supported by strong gross margin expansion.

Poly Medicure’s (Polymed) Q2FY23 performance beats our estimates on all fronts.
Revenue grew 23.0% YoY to Rs2.7bn (I-Sec: Rs2.6bn) led by strong demand across segments.

Poly Medicure’s (Polymed) Q1FY23 performance was a miss on the profitability front due to lower margins while revenues were on expected lines.

wellness products, including medicines, vitamins, medical devices and test kits, and (ii) fast-moving consumer goods, such as home and personal care products, including toiletries, baby care products, soaps and detergents, and sanitizers. Medplus has 3 manufacturing plants in Telangana, manufacturing range...

Issue Snapshot: Issue Open: Dec 13 Dec 15 2021 Price Band: Rs. 780 796 (Discount of Rs 78 for All eligible employees) *Issue Size: Rs 1398.3 cr (Fresh issue of Rs 600 cr + Offer for sale of Rs 798.3 cr) Reservation for: QIB Upto 50% eq sh Non Institutional atleast 15% eq sh Retail atleast 35% eq sh Employee: upto Rs 5 cr Face Value: Rs 2 Book value: Rs 73.71 (Sep 30, 2021) Bid size: - 18 equity shares and in multiples thereof 100% Book built Issue Medplus Health Services Limited - IPO Note

Medplus Health Services is the second largest pharmacy retailer in India, in terms of (i) revenue from operations for the financial year 2021, and (ii) number of stores as of March 31, 2021. Company offer a wide range of products, including (i) pharmaceutical and wellness products, including medicines, vitamins, medical devices and test kits, and (ii) fast-moving consumer goods, such as home and personal care products,...

IPO NOTE

18 Equity Shares and in multiples thereof. Public issue of 17,566,520 Equity shares of Face value Rs. 2 each, (Comprising of fresh issue of 7,537,688 Equity Shares* (Rs. 600 cr.) and Offer for Sale of...

Medplus Health Services Limited was incorporated in November 2006 by Gangadi Madhukar Reddy with other promoters. Medplus is the 2nd largest pharmacy retailer in India, in terms of the number of stores as of March 31, 2021, and in terms of revenue from the operation. Medplus offers a wide range of pharmaceutical products and fast-moving